BIRC5 and gastric cancer: Interestingly, in terms of the diverse mechanisms of survivin upregulation, preclinical data have shown that survivin can be upregulated by EBV latent genes and is considered to contribute chemoresistance and poor clinical outcomes in EBV-associated malignancies such as EBV-positive gastric cancer and EBV-positive DLBCL [20, 21].